Presentation on 5 November 2013 is part of a pre-conference workshop on Bioequivalence for Inhaled Products, taking place ahead of the Management Forum Inhaled Drug Delivery (IDD) conference
Mark Copley, Sales Director for Copley Scientific
Mark Copley, Sales Director for Copley Scientific, will discuss optimal testing strategies for the development of inhaled generic products at a specialist meeting in London, UK, in November. His invited presentation on 5 November 2013 is part of a pre-conference workshop on Bioequivalence for Inhaled Products, taking place ahead of the Management Forum Inhaled Drug Delivery (IDD) conference on 6 November. Both are being held at The Rembrandt Hotel, London.
The pre-conference workshop and the full conference programme include presentations from a number of leading industrialists and will cover current trends in inhaled drug delivery technology and regulation. To register for the workshop, or to find out more, please visit: www.management-forum.co.uk/pharmaceutical/eventid/2357#.UmaSHjuTxzp.
Copley’s presentation ‘Methodologies for in vitro bioequivalence testing of generic inhaled products’, will examine the laboratory tests that can be used to demonstrate that a generic product delivers equivalent clinical efficacy to a reference labelled drug.
Generic inhaled drug development is a fast-growing area of the pharmaceutical industry. A primary focus is the commercialisation of inexpensive, efficient products for treating asthma and chronic obstructive pulmonary disease (COPD). Demonstrating bioequivalence through in vitro testing minimises the need for clinical trials, accelerating time to market and reducing development costs. Copley will review the regulatory framework in this area and outline efficient testing strategies designed to fulfil the associated requirements.
As the world’s leading manufacturer and supplier of inhaler test equipment, Copley Scientific has a range of innovative new products to meet evolving requirements for both novel and generic inhaled product testing. Extensive company expertise supports the optimal application of these products to advance inhaled product development.